---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056519"
form_type: "8-K"
ticker: "DRIO"
cik: "0001533998"
company_name: "DarioHealth Corp."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:39:43.967950+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DarioHealth completes $15.4M preferred stock placement and $30M credit facility refinancing

## Summary
- Raised ~$15.4M via convertible preferred stock (Series B, B-1, B-2, B-3) at $1,000/share; conversion prices $3.334-$3.392.
- New $30M secured credit facility from Avenue Venture Funds; $30M initial tranche closed; up to $10M additional available after July 2023.
- Proforma cash $60M after transactions; expects cash runway through late 2025; saves ~$6M annually in amortization payments.
- Approximately half of preferred shares bought by insiders, including management and board; Avenue receives warrant for 584,882 shares at $3.334.

## SEC filing metadata
- accession: 0001104659-23-056519
- form_type: 8-K
- ticker: DRIO
- cik: 0001533998
- company_name: DarioHealth Corp.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/tm2314673d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056519
- JSON: https://secwatch.observer/filing/0001104659-23-056519.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056519.txt

## Key facts
- Governance Changes
  DarioHealth Corp.: Filed certificates of designation for Series B, B-1, B-2, and B-3 Preferred Stock, specifying rights and preferences (effective 2023-05-01).
  - Change: charter amendment
  - Effective: 2023-05-01
  source text: On May 1, 2023, the Company filed the Series B Certificate of Designation, designating 30,000 shares of Series B Preferred Stock, the Series B-1 Certificate of Designation, designating 15,000 shares of Series B-1 Preferred Stock, and the Series B-2 Certificate of Designation, designating 15,000 shares of Series B-2 Preferred Stock in connection with the Offering. On May 5, 2023, the Company filed the Series B-3 Certificate of Designation, designating 15,000 shares of Series B-3 Preferred Stock in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm
- Material Agreements
  DarioHealth Corp. entered into Series B Purchase Agreement with accredited investors (effective 2023-05-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited investors
  - Effective: 2023-05-01
  source text: On May 1, 2023, DarioHealth Corp. (the "Company") entered into securities purchase agreements (each, a "Series B Purchase Agreement") with accredited investors relating to an offering (the "Offering") and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the "Series B Preferred Stock"), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the "Series B-1 Preferred Stock"), and an aggregate of 150 shares of Series B-2 Preferred Stock (the "Series B-2 Preferred Stock") at a purchase price of $1,000 for each share of Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm
- Material Agreements
  DarioHealth Corp. entered into Series B-3 Purchase Agreement with accredited investors (effective 2023-05-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited investors
  - Effective: 2023-05-05
  source text: On May 5, 2023, the Company entered into purchase agreements (the "Series B-3 Purchase Agreement" and together with the Series B Purchase Agreement, the "Purchase Agreement") with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the "Series B-3 Preferred Stock" and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the "Preferred Stock"), at a purchase price of $1,000 for each share of Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.